Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1296950-66-7 | MDL No. : | MFCD18909573 |
Formula : | C10H7BrN2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ACZBTKDTNZGKAF-UHFFFAOYSA-N |
M.W : | 251.08 g/mol | Pubchem ID : | 69085329 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 10 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 57.54 |
TPSA : | 55.98 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.59 cm/s |
Log Po/w (iLOGP) : | 1.6 |
Log Po/w (XLOGP3) : | 1.75 |
Log Po/w (WLOGP) : | 2.1 |
Log Po/w (MLOGP) : | 1.64 |
Log Po/w (SILICOS-IT) : | 2.23 |
Consensus Log Po/w : | 1.86 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.96 |
Solubility : | 0.274 mg/ml ; 0.00109 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.54 |
Solubility : | 0.72 mg/ml ; 0.00287 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.15 |
Solubility : | 0.0179 mg/ml ; 0.0000713 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.42 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In 1,4-dioxane at 130℃; for 0.416667h; Microwave irradiation; | 26.c (+)-9-[4-(3-chloro-7-quinolinyl)-2,6-difluorophenyl]methyl}-4-cyclopropyl-1-oxa-4,9-diazaspiro[5.5]undecane-3,8-dione General procedure: A 5 mL microwave vial equipped with a stirbar was charged with 7-bromo-3-chloroquinoline (152 mg, 0.629 mmol) and PdCI2(dppf)-CH2CI2 adduct (29.9 mg, 0.037 mmol). The solids were taken up in 1 ,4-dioxane (0.546 mL) and treated with a 0.338M 1 ,4-dioxane solution of 4-cyclopropyl-9-(2,6-difluoro-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzyl)-1-oxa-4,9-diazaspiro[5.5]undecane-3,8-dione (1.55 mL, 0.524 mmol). The mixture was treated with 2M aq potassium carbonate (0.524 mL, 1.048mmol). The vial was sealed and the mixture subjected to microwave irradiation at130 °Cfor2S mm on very high absorption setting (Biotage Initiator 60). The mixture was then cooled to room temperature and partitioned between 15 mL each of chloroform and saturated aq sodium bicarbonate. The mixture was separated, the organic layer isolated, and the aqueous layer re-extracted with an additional 15 mL chloroform. The organicswere then pooled, dried over sodium sulfate, filtered, and concentrated to a residue. The residue was purified by flash chromatography (0.3-5.5% methanol:dichloromethane). Fractions containing the desired material were pooled and concentrated to a residue which was then resolved by chiral HPLC (Chiralpak AS-H, 95:5 acetonitrile:methanol) to afford title compound in 100% ee as a white solid (58 mg, 0.112 mmol, 21% yield). c) (±)-7-(4-((4-cyclopropylC-3,8-d ioxo-1 -oxa-4, 9-diazaspiro[5 .5]undecan-9-yl)methyl)-3,5-difluorophenyl)quinoline-3-carboxamideFollowing the procedure described in Example 7c with 7-bromoquinolin-3- carboxamide afforded the title product (37% yield). MS(ES)+ m/e 521.2 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sulfuric acid; acetic acid at 90℃; | 26.b 7-bromoquinolin-3-carboxamide A 40 mL reaction vial equipped with a stirbar was charged with 7-bromoquinoline- 3-carbonitrile (200 mg, 0.858 mmol). The solid material was taken up in acetic acid (4 mL), treated with sulfuric acid (229 p1, 4.29 mmol), and the resulting mixture stirred overnight at 90 °C. The mixture was then cooled to room temperature and carefullyneutralized with -20 mL saturated aqueous sodium carbonate solution. The resulting white precipitate was collected by suction filtration to afford crude material used in the next step without further purification (176 mg, 0.701 mmol, 82% yield). MS(ES)+ m/e 250.8 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: sodium hydroxide / methanol / 18 h / 110 °C / Microwave irradiation; Sealed tube 2: chloroformic acid ethyl ester; triethylamine / tetrahydrofuran / 0.17 h / 0 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
76% | Stage #1: 7-bromoquinoline-3-carboxylic acid With chloroformic acid ethyl ester; triethylamine In tetrahydrofuran at 0℃; for 0.166667h; Stage #2: With ammonia In tetrahydrofuran; 1,4-dioxane | 19.b b) 7-bromoquinoline-3-carboxamide b) 7-bromoquinoline-3-carboxamideTo a 0 °C solution of 7-bromoquinoline-3-carboxylic acid (500 mg, 1.984 mmol)tetrahydrofuran (20 mL) was added ethyl chloroformate (0.451 mL, 4.70 mmol) followedtriethylamine (0.7 19 mL, 5.16 mmol). The mixture was stirred for 10 minutes after whichtime the solid precipitate was filtered off. To the filtrate was added 0.5 M ammonia in dioxane (20 mL) and the resulting mixture was stirred at room temperature for 1 h. The solvents were evaporated under reduced pressure and the resulting white solid was washed with water on a filter to afford the title compound (398 mg, 76%). MS(ES)+ mle 251 [M+H]. |
[ 1296950-96-3 ]
6-Bromoquinoline-3-carboxamide
Similarity: 0.98
[ 1823338-54-0 ]
5-Bromoquinoline-8-carboxamide
Similarity: 0.96
[ 1823931-71-0 ]
6-Bromoquinoline-8-carboxamide
Similarity: 0.94
[ 1211596-82-5 ]
4-Bromo-1H-indole-7-carboxamide
Similarity: 0.93
[ 860624-91-5 ]
5-bromo-1H-indole-7-carboxamide
Similarity: 0.91
[ 1296950-96-3 ]
6-Bromoquinoline-3-carboxamide
Similarity: 0.98
[ 1823338-54-0 ]
5-Bromoquinoline-8-carboxamide
Similarity: 0.96
[ 1823931-71-0 ]
6-Bromoquinoline-8-carboxamide
Similarity: 0.94
[ 1211596-82-5 ]
4-Bromo-1H-indole-7-carboxamide
Similarity: 0.93
[ 860624-91-5 ]
5-bromo-1H-indole-7-carboxamide
Similarity: 0.91
[ 1296950-96-3 ]
6-Bromoquinoline-3-carboxamide
Similarity: 0.98
[ 1823338-54-0 ]
5-Bromoquinoline-8-carboxamide
Similarity: 0.96
[ 1823931-71-0 ]
6-Bromoquinoline-8-carboxamide
Similarity: 0.94
[ 1211596-82-5 ]
4-Bromo-1H-indole-7-carboxamide
Similarity: 0.93
[ 860624-91-5 ]
5-bromo-1H-indole-7-carboxamide
Similarity: 0.91
[ 1296950-96-3 ]
6-Bromoquinoline-3-carboxamide
Similarity: 0.98
[ 1823338-54-0 ]
5-Bromoquinoline-8-carboxamide
Similarity: 0.96
[ 1823931-71-0 ]
6-Bromoquinoline-8-carboxamide
Similarity: 0.94
[ 1823954-00-2 ]
7-Bromoquinoline-8-carboxamide
Similarity: 0.89